Latest News
Research awarded by BrightFocus totals nearly $290 million to date across 25 countries, enabling innovative scientists from around the world to push the boundaries of Alzheimer’s, macular degeneration, and glaucoma research.
Donanemab, a potential new amyloid-clearing Alzheimer’s drug, has been shown to slow cognitive decline by 35% in the early stages of Alzheimer’s disease.
Blacks and Hispanics with neuropsychiatric symptoms are more likely to develop cognitive impairment, according to recent BrightFocus-funded research.
A BrightFocus-funded research team has identified how an FDA-approved antioxidant may be used to help prevent age-related macular degeneration in people with certain genetic risk factors for the disease.
The U.S. Food and Drug Administration today granted full approved of Leqembi (lecanemab-irmb) for the treatment of Alzheimer’s disease based on its ability to clear toxic amyloid from the brain.
Initial study results of an innovative glaucoma therapy involving eye implants have yielded positive results, and a Phase 2 clinical trial of this exciting potential treatment has begun.
BrightFocus Foundation hosted its 50th Anniversary Celebration and Awards on June 14 at the Smithsonian’s National Museum of the American Indian in Washington, D.C.
On Wednesday, June 14, BrightFocus hosted a bipartisan congressional briefing to highlight the importance of funding and diversity in research to improve health equity and cure brain and vision diseases.
In a finding that raises new questions about the connection between amyloid plaques and Alzheimer’s disease, a Dutch study showed people over age 100 maintained sharp minds despite having brain changes associated with dementia.
Factors that stress the body, such as obesity, can make people more likely to develop macular degeneration when they’re older, even if they’ve returned to a normal weight, new research shows.
